Brief: Eledon Pharmaceuticals Inc - Announces Update On Development Strategy For At-1501 In Renal Transplantation

Eledon Pharmaceuticals

26/04/2021 21:18

April 26 (Reuters) - Eledon Pharmaceuticals Inc  ELDN.O :
    * ELEDON PHARMACEUTICALS INC - ANNOUNCES UPDATE ON
DEVELOPMENT
STRATEGY FOR AT-1501 IN RENAL TRANSPLANTATION
    * ELEDON PHARMACEUTICALS INC - FDA REQUESTED CO PROVIDE
AT-1501
SPECIFIC, RENAL TRANSPLANT DATA IN NON-HUMAN PRIMATES PRIOR TO
INITIATING PHASE 2 TRIAL
    * ELEDON - PLANS TO INITIATE EVALUATION OF AT-1501 IN
STANDARD
NON-HUMAN PRIMATE MODEL OF RENAL TRANSPLANTATION, EXPECTED TO BE
COMPLETED BY LATE 2022
    * ELEDON PHARMACEUTICALS INC - WILL CONTINUE TO EXPLORE
POTENTIALLY CONDUCTING A RENAL TRANSPLANTATION CLINICAL TRIAL
OUTSIDE UNITED STATES
    * ELEDON PHARMACEUTICALS INC - FDA REQUEST AND SHIFT IN
DEVELOPMENT STRATEGY IS SPECIFIC TO PREVIOUSLY PLANNED PHASE 2
TRIAL IN RENAL TRANSPLANTATION
    * ELEDON PHARMACEUTICALS INC - NO SIGNIFICANT DRUG-RELATED
SAFETY
SIGNALS WITH AT-1501 HAVE BEEN IDENTIFIED TO DATE

Source text for Eikon:  ID:nGNX2r2PdR 
Further company coverage:  ELDN.O 

 ((Reuters.Briefs@thomsonreuters.com;))